Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Hansa Biopharma AB ( (SE:HNSA) ).
Hansa Biopharma AB has announced an Extraordinary General Meeting scheduled for September 2, 2025, to discuss several key resolutions, including the election of new members to the Board of Directors. The Nomination Committee has proposed the election of Elisabeth Björk, Natalie Berner, and Michael Bologna as new board members, with remuneration details outlined for various committee roles. This meeting is significant for the company’s governance structure, potentially impacting its strategic direction and stakeholder engagement.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a biopharmaceutical company based in Lund, Sweden, focused on developing innovative immunomodulatory treatments for rare diseases. The company is known for its enzyme technology platform, which is aimed at addressing unmet medical needs in transplantation and autoimmune diseases.
Average Trading Volume: 306,357
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.6B
For a thorough assessment of HNSA stock, go to TipRanks’ Stock Analysis page.